KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.

Amy McMichael, Mona Shahriari, Linda Stein Gold, Theodore Alkousakis, Olivia Choi, Tina Bhutani, Adrian O Rodriguez, Stephen K Tyring, Daphne Chan, Katelyn Rowland, Lorne Albrecht, Charles Lynde, Geeta Yadav, Jensen Yeung, Laura Park-Wyllie, Tony Ma, Jenny Jeyarajah, Long-Long Gao, Stacy Smith, Angela Y Moore, Neelam Vashi, Chesahna Kindred, Pearl Grimes, Seemal R Desai, Susan C Taylor, Andrew Alexis, VISIBLE Trial Investigators

JAMA Dermatol 161(9) 912-922

PMID40560554
PMCIDPMC12199185
DOI10.1001/jamadermatol.2025.1849
发表日期2025-06-25
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:AI 判定为 other;Figure 3.:AI 判定为 other。
摘要

摘要

IMPORTANCE: Varying hair textures and hair care practices contribute to nuances in clinical presentation and management of scalp psoriasis across diverse patient populations. Cohort B of the VISIBLE trial enrolled participants with moderate to severe scalp psoriasis and skin of color, across the skin-tone spectrum. OBJECTIVE: To evaluate efficacy, quality of life, and adverse event outcomes of guselkumab, 100 mg, among participants with moderate to severe scalp psoriasis and skin of color over 48 weeks. DESIGN, SETTING, AND PARTICIPANTS: This ongoing phase 3b, randomized clinical trial at 45 sites in the US and Canada enrolled adults with skin of color and moderate to severe scalp psoriasis (scalp surface area [SSA] ≥30%; Psoriasis Scalp Severity Index [PSSI] ≥12; scalp-specific Investigator's Global Assessment [ss-IGA] score ≥3; ≥1 nonscalp plaque). Data were collected from September 2022 to June 2024. INTERVENTIONS: Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0, 4, and every 8 weeks, or placebo at weeks 0, 4, and 12, then guselkumab at weeks 16, 20, and every 8 weeks. MAIN OUTCOMES AND MEASURES: Coprimary end points were ss-IGA score of 0 or 1 (ss-IGA 0/1) and 90% or greater improvement in PSSI (PSSI 90) at week 16 (guselkumab vs placebo). Major secondary end points included ss-IGA 0 (complete scalp clearance), PSSI 100, percentage changes from baseline in PSSI and SSA, changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms score, and 4-point or greater reduction in Scalp Itch Numeric Rating Scale (NRS) score. RESULTS: Of 108 participants (81 randomized to guselkumab; 27 randomized to placebo), 100 (92.6%) completed 48 weeks of treatment. The mean (SD) age overall was 42.5 (13.6) years, and 58 participants (56.9%) were male. At the week 16 primary end point, in the guselkumab (n = 76) vs placebo (n = 26) groups, respectively, response rates were as follows: ss-IGA 0/1, 68.4% (n = 52) vs 11.5% (n = 3) (P < .001); PSSI 90, 65.8% (n = 50) vs 3.8% (n = 1) (P < .001); ss-IGA 0, 57.9% (n = 44) vs 3.8% (n = 1) (P < .001); PSSI 100, 59.2% (n = 45) vs 3.8% (n = 1) (P < .001); 4-point or greater reduction in Scalp Itch NRS score (in those with a baseline score of at least 4), 69.4% (n = 50 of 72) vs 24.0% (n = 6 of 25) (P < .001). Guselkumab efficacy increased and was maintained through week 48, when guselkumab-randomized participants achieved mean (SD) percentage improvements in PSSI and SSA of 94.6% (12.2%) and 94.8% (16.2%), respectively, and 51 (67.1%) achieved ss-IGA 0. DLQI and PSSD symptoms score least-squares mean changes were -9.7 (95% CI, -11.1 to -8.2) vs -2.2 (95% CI, -4.8 to 0.4) (P < .001) and -44.8 (95% CI, -50.6 to -39.1) vs -8.3 (95% CI, -18.4 to 1.9) (P < .001), respectively, with sustained improvements through week 48. Through week 16, infections were the most common adverse events in the guselkumab (n = 12; 14.8%) and placebo (n = 1; 3.7%) groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, after 3 doses of guselkumab, most participants achieved significant scalp clearance and clinically meaningful quality-of-life improvements; improvements increased and were maintained through week 48. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05272150.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.VISIBLE Cohort B Study Design and Participant Disposition Through Week 48 a Coprimary end points are the proportions of participants achieving scalp-specific Investigator’s Global Assessment 0 or 1 and 90% improvement in Psoriasis Scalp Severity Index at week 16.
非 KM Figure
Figure 2.Clinical Responses in VISIBLE Cohort B Through Week 48 Proportions of participants achieving scalp-specific Investigator’s Global Assessment (ss-IGA) score of 0 or 1 (A), 90% or greater improvement in Psoriasis Scalp Severity Index (PSSI 90) (B), ss-IGA score of 0 (C), and PSSI 100 (D). The mean percentage improvement in PSSI and scalp surface area (SSA) over time is also presented (E and F). a Week 16, P < .001 for guselkumab vs placebo. b For participants who were randomized to placebo at week 0, only those who crossed over to guselkumab at or after week 16 were included in analyses after week 16. c Week 16, P < .001 for guselkumab vs placebo based on the mixed-effects model for repeated measures.
非 KM Figure
Figure 3.Patient-Reported Outcomes in VISIBLE Cohort B Proportions of participants achieving Dermatology Life Quality Index (DLQI) of 0 or 1 (A); mean Scalp Itch numeric rating scale (NRS) score (B); and mean overall Psoriasis Symptoms and Signs Diary (PSSD) symptoms scores (C). a Among participants with DLQI of greater than 1 at baseline. b Week 16, nominal P = .003 for guselkumab vs placebo. c For participants randomized to placebo at week 0, only those who crossed over to guselkumab at or after week 16 were included in analyses after week 16. d Week 16, P < .001 for guselkumab vs placebo based on the analysis of covariance model. e Week 16, P < .001 for guselkumab vs placebo based on the mixed-effects model for repeated measures. f PSSD assessments were optional at weeks 28 and 36.
非 KM Figure